New hope for tough kidney cancer cases: testing a Double-Acting drug combo
NCT ID NCT06730932
Summary
This study is testing a new two-drug combination for people with advanced kidney cancer that has spread or cannot be removed by surgery, and whose cancer has gotten worse after previous immunotherapy. The trial will see if adding a new drug called JS004 to an existing immunotherapy drug (toripalimab) can help control the cancer. About 31 participants will receive the drug combination until their cancer grows, side effects become too severe, or they choose to stop.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE OR ADVANCED CLEAR CELL RENAL CELL CARCINOMA THAT HAS PROGRESSED AFTER PREVIOUS IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200127, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.